Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. COVID-19 vaccine supplies strain to meet wider eligibility, second doses

Published 2021-01-16, 07:04 p/m
Updated 2021-01-16, 07:06 p/m

By Peter Szekely

NEW YORK (Reuters) - Scattered shortages of COVID-19 vaccines persisted on Saturday under pressure from growing demand, as previously inoculated Americans returned for their required second shots and millions of newly eligible people scrambled to get their first.

The supply gaps, coming as the U.S. vaccination effort enters its second month, prompted some healthcare systems to suspend appointments for first-time vaccine seekers and one New York healthcare system to cancel a slew of existing ones.

"As eligibility increases, you just increase demand, but we're not able to increase supply," Northwell Health spokesman Joe Kemp told Reuters by telephone.

Northwell, New York's largest healthcare provider, offers appointments only as it gets more vaccine, and only after allocating doses to people scheduled for their second shots, Kemp said.

Although the supply flow has been sporadic, Northwell expects to offer appointments in the coming week, he added.

Both approved vaccines, one from Pfizer Inc (NYSE:PFE) and BioNTech and the other from Moderna Inc, require a booster three to four weeks after the first shot to maximize their effectiveness against the coronavirus.

While healthcare workers and nursing home residents and staff got first priority, eligibility for the vaccines has since widened, with some states opening it to healthy people aged 65 and up and people of any age with pre-existing conditions.

Besides New York, signs of vaccine supply strains appeared in Vermont, Michigan, South Carolina, New Jersey and Oregon.

In Oregon, Governor Kate Brown said vaccinations for seniors and educators would be delayed, while Vermont Governor Phil Scott said the state would focus exclusively on its over-75 population because of "unpredictable” federal supplies.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

NOT "OVER-PROMISING"

“Rather than over-promising a limited supply to a broad population that we know we can’t vaccinate all at once, we believe our strategy will get shots in arms faster and more efficiently, with less loss of life,” Scott said on Twitter.

New York Governor Andrew Cuomo said last week that the looser requirements would make 7 million of New York's 19 million residents eligible for inoculations.

New York's Mount Sinai Hospital said on Friday that it canceled vaccination appointments through Tuesday because of "sudden changes in vaccine supply."

An official at NYU Langone Health, another healthcare giant, said it has indefinitely suspended new appointments because it had received no confirmation that it would get more vaccine.

New York City Mayor Bill de Blasio said on Friday that while the city was ramping up its vaccination capacity, supplies were still coming in at "a very paltry" 100,000 doses a week, which put it on course to run dry in the coming week.

De Blasio was among three dozen big city mayors who asked the incoming Biden administration last week to send COVID-19 vaccine shipments directly to them, bypassing state governments.

Jack Sterne, a spokesman for the state, blamed the supply problems on the federal government, which he said was cutting New York's vaccine shipment in the coming week by 50,000 doses to 250,000.

"The problem all along has been a lack of allocation from Washington, and now that we've expanded the population of those eligible, the federal government continues to fail to meet the demand," Sterne said by email.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Adding to the inter-governmental tension was a squabble in which several governors accused the Trump administration on Friday of deceptively pledging to distribute millions of COVID-19 vaccine doses from a stockpile that the U.S. health secretary has since acknowledged does not exist.

Since the first vaccine was administered in the United States in mid-December, nearly 12.3 million doses have been given, out of 31.2 million doses distributed, according to the Centers for Disease Control and Prevention. The total includes 1.6 million people who have received both doses, the CDC said.

Since the onset of the pandemic, 23.4 million Americans have been infected with the coronavirus, 392,153 of whom died, according to a Reuters tally.

While seriously ill patients are straining healthcare systems in parts of the country, especially in California, the national rate of hospitalizations has leveled off in the past two weeks and was at 127,095 on Friday.

A widely cited model by the University of Washington projects that January will be the deadliest month of the pandemic, claiming more than 100,000 lives.

But the newly revised model of the university's Institute for Health Metrics and Evaluation projects that the monthly toll will abate thereafter, shrinking to about 11,000 in April, as more people are vaccinated.

"By May 1, some states may be close to herd immunity," the IHME said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.